Multiple Sclerosis. a diagnostic guide. Springer Healthcare Education
|
|
- Roy Jenkins
- 7 years ago
- Views:
Transcription
1 Multiple Sclerosis a diagnostic guide Derived from Handbook of Multiple Sclerosis by Jeffrey A Cohen and Alexander Rae-Grant
2 Introduction Defining multiple sclerosis Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) that produces demyelination and axonal/neuronal damage, resulting in characteristic multifocal lesions on magnetic resonance imaging (MRI) and a variety of neurologic manifestations. This guide will provide a broad summary of diagnosing multiple sclerosis, including clinical features and diagnostic criteria. Please refer to the Handbook of Multiple Sclerosis for further information, including treatment options. Key clinical features Typical onset is in the age range years Female predominance approximately 2.5:1 Neurologic manifestations reflect multifocal involvement of the CNS (brain, spinal cord, optic nerves) Nonfocal manifestations (eg, cognitive impairment, mood disorders, pain, and fatigue) also significantly contribute to disability Relapsing remitting (RR) course at onset in 70 80% of patients, usually evolving into a secondary progressive phase Progressive course from onset in ~20% of patients Most patients develop disability over years The range and severity of clinical manifestations have marked heterogeneity, both in individual patients over time and between patients Diagnosis is straightforward in typical patients, but differential diagnosis is extensive when there are atypical features Effective therapies are available and should be considered early to lessen the risk of permanent disability Treatment of symptoms and addressing psychosocial sequelae are important aspects of management Objectives for patient care It is important to make a diagnosis of MS accurately and expeditiously to relieve uncertainty and allow the institution of disease-modifying therapy. The purpose of therapy is to decrease relapses and MRI activity, with the ultimate goal of reducing the long-term risk of permanent disability. Because of the myriad of potential manifestations that interfere with function and negatively impact quality of life, symptom management is also an important aspect of management.
3 Epidemiology and Genetics Prevalence and risk factors The prevalence of MS is approximately 1/1000, affecting approximately 400,000 people in the USA and 2 million worldwide [1]. MS is the most common nontraumatic cause of neurologic disability in young adults. Onset typically is between the ages of 20 and 40 years and women are affected more frequently than men. Approximately 70% of monozygotic twins are discordant for MS, implying an interaction between the genetic propensity for MS and environmental factors. There is a distinct latitude gradient: MS is relatively rare in the tropics and increases in prevalence with increasing latitude in both the northern and southern hemispheres. Migration studies suggest that risk of acquiring MS is determined at/before puberty. Postulated risk factors include infectious agents, diet, environmental toxins, and sunlight [2], but none has been definitively implicated. Genetic susceptability to MS Relatives of patients with MS are at increased risk for the disease and several lines of evidence indicate that MS has a genetic component [2,3]. However, the genetic basis of MS is complex (ie, multiple genes contribute cumulatively to the risk of MS and disease behavior) and is heterogeneous (ie, the genes and alleles involved probably differ from patient to patient). Genetic studies have most consistently implicated genes encoded in the class II region of the major histocompatibility complex (MHC) on chromosome 6 [4] Monozygotic twin Child of conjugal MS pair Child Sibling First cousin Adopted siblings General population Population-based prevalence of MS (per 1000) in relatives of patients with MS [5].
4 Pathogenesis and Prognosis Pathogenesis Pathology The pathology of MS is characterized by multifocal lesions within the CNS, both in the white matter and gray matter, with perivenular inflammatory cell infiltrates, demyelination, axonal transection, neuronal degeneration, and gliosis [6]. A B n CSO at io cortex Ed uc CC white matter lesion cortical lesion CSO re LV Sp rin ge rh ea l th ca Pathology of MS. (A) Demyelinated lesion in periventricular white matter. (B) Demyelinated lesion in cortex. CSO, centrum semiovale; CC, corpus callosum; LV, lateral ventricle. High-power view of a white matter lesion in MS. This confocal micrograph shows demyelination (arrowheads) and axonal transection (arrow).
5 Pathogenesis Pathogenesis Traditional theory postulates that myelin-specific CD4 + T cells play a central role in the pathogenesis of MS (see figure below). CD4 + T cell subsets, natural killer cells, monocytes/macrophages, B cells, and humoral factors have also been implicated [7]. A large number of biopsy and autopsy specimens suggested that the mechanisms leading to tissue damage differ from patient to patient [8]. Inflammatory mechanisms predominate early in the disease, but the gradual worsening in primary progressive (PP) and secondary progressive (SP) MS is due to neurodegeneration. Lymphoid tissue B cells Dendritic cell T cells T helper cell Antigens CD8 + cells Neuron B cell Oligodendrocyte Plasma cell Antibodies CD4 + cells Cytokines Microglia Hypothetical view of immune response in acute multiple sclerosis lesion. T- and B-cell responses are primed in the peripheral lymphoid tissue by antigens. After clonal expansion, T and B cells infiltrate the CNS. Clonally expanded B cells re-encounter their specific antigen, mature to plasma cells, and release large amounts of antibodies. These antibodies bind soluble or membrane-bound antigen on expressing cells. Clonally expanded CD8+ T cells also invade the brain and could encounter their specific peptide ligand, presented by glial or neuronal cells on MHC class I molecules. The recognition of specific MHC-peptide complexes on these cells prompts direct damage to expressing cells. CD4+ T cells migrate into the CNS and encounter antigens that are presented by microglial cells on MHC class II molecules. Reactivation of these cells leads to heightened production of inflammatory cytokines that attract other immune cells, such as macrophages, which contribute to inflammation through the release of injurious immune mediators and direct phagocytic attack on the myelin sheath. Figure reproduced with permission from Hemmer et al [9] Nature. CNS
6 Clinical Presentation Clinical manifestations The wide range of symptoms and signs of MS reflect multifocal lesions in the CNS, including in the afferent visual pathways, cerebrum, brainstem, cerebellum, and spinal cord. Not all symptoms will be present in every patient and can vary greatly between patients. Typical clinical manifestations of MS Category Description Visual Visual loss: monocular (pre-chiasmatic) or homonymous (post-chiasmatic), double vision, oscillopsia Vestibular Vertigo, lack of balance Bulbar Dysarthria, swallowing dysfunction dysfunction Motor Weakness, spasticity, incoordination, tremor Sensation Sensory loss: any modality or distribution Positive sensory phenomena: paresthesias, dysesthesias, neuropathic pain Gait impairment Varying contributions from visual impairment, vestibular symptoms, weakness, spasticity, ataxia, imbalance, sensory loss, pain, and fatigue Urinary Urgency, frequency, hesitancy, retention, incontinence, frequent urinary symptoms tract infections Bowel symptoms Constipation, urgency, incontinence, bladder spasms Sexual Decreased libido, erectile dysfunction, anorgasmia dysfunction Cognitive Poor concentration or attention, slowed thinking, poor memory (particularly impairment short-term), impaired executive function Mood disorders Depression, anxiety, affective release Fatigue Handicap fatigue: increased effort to perform routine tasks Motor fatigue: decreased performance or endurance with sustained effort Heat intolerance: worsening symptoms with increased body temperature Systemic fatigue: persistent lassitude Pain Chronic neuropathic pain, paresthesias, dysesthesias Paroxysmal sensory symptoms (eg, neuralgic pain) Spasticity: spasms, uncomfortable increased muscle tone Proxysmal motor phenomena (eg, tonic spasms) Pain associated with acute inflammatory lesions and irritation of adjacent meninges (eg,optic neuritis, chronic photophobia following optic neuritis) Mechanical back or joint pain from immobility Compression fractures Paroxsymal phenomena Epileptic seizures Nonepileptic paroxysmal motor phenomena (eg, paroxysmal dystonia) Nonepileptic paroxysmal sensory phenomena (eg, Lhermitte s phenomena) Uthoff s phenomenon
7 Clinical Presentation Disease course The course of MS is categorized based on how clinical manifestations develop over time and on the severity and tempo of the disease [10]. MS begins with a RR course in 70 80% of patients. A relapse (or exacerbation or attack) is defined by the following characteristics: new, worsening, or recurrent neurologic symptoms consistent with MS, typically develops over days to weeks, lasts at least hours, and accompanied by an objective change on the neurologic examination corresponding to the patient s symptoms [11]. Relapses are heterogeneous within and between patients in terms of neurologic manifestations, frequency, severity, and degree of recovery. The diagnosis of RR MS is confirmed when recurrent CNS inflammatory events occur (either a second relapse or new MRI lesion activity). When a patient has had only a single relapse, the initial event is called a clinically isolated syndrome (CIS). Even without treatment, most relapses recover partially or completely over weeks to months, particularly early in the disease; however, not all relapses recover completely, and early in the disease most impairment/disability accrual is the result of incomplete relapse recovery [12]. After years, most patients with RR MS exhibit gradual worsening of disability, known as the SP phase. Approximately 15% of patients with MS demonstrate gradual worsening disability from onset, known as primary progressive (PP) MS. Other categories of MS include progressive-relapsing (~5% of patients), fulminant (~5%), and benign (~10 20% of patients). Categories of multiple sclerosis CIS One episode of inflammatory CNS demyelination RR MS Recurrent episodes of inflammatory CNS inflammation with stable clinical manifestations between episodes SP MS Gradual neurologic deterioration, with or without superimposed relapses, in a patient with prior RR MS PP MS Gradual neurologic deterioration from onset without superimposed relapses Progressiverelapsing Fulminant Benign Gradual neurologic deterioration from onset with subsequent superimposed relapses Severe MS with frequent relapses and/or rapid disability progression MS that remains mild over a prolonged course with rare relapses and minimal disability accumulation
8 Clinical presentation RR SP Neurologic Impairment CIS Time (years) Typical disease course in relapsing MS. The initial relapse is a CIS. The diagnosis of RR MS is confirmed when a second clinical/mri event occurs. In RR MS, disability accrues from incomplete recovery from relapses. Relapses vary in neurologic manifestations, frequency, severity, and degree of recovery. Most patients evolve into an SP course years after onset, although the transition is indistinct, with decreasing relapse frequency and onset of gradual worsening between relapses. Late in the disease, there is gradual progression without relapses. 1. Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. 2004;3: Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008;7: Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol. 2004;3: The International Multiple Sclerosis Genetics Consortium. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet. 2005;77: The International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357: Lucchinetti CF, Parisi J, Bruck W. The pathology of multiple sclerosis. Neurol Clin. 2005;23: Frohman EM, Racke MK, Raine CS. Multiple sclerosis the plaque and its pathogenesis. N Engl J Med. 2006;354: Morales Y, Parisi JE, Lucchinetti CF. The pathology of multiple sclerosis: evidence for heterogeneity. Adv Neurol. 2006;98: References 9. Hemmer B, Archelos JJ, Hartung H-P. New concepts in immunopathogenesis of multiple sclerosis. Nat Rev Neurosci. 2002;3: Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology. 1996;46: Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol. 2005;58: Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61: Traboulsee A, et al. Revised recommendations of the CMSC task force for standardized MRI protocol and clinical guidelines for MS. CMSC website. Accessed May 19, Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. Ann Neurol. 2011;69: Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008;14: Source material: Cohen JA, Rae-Grant A. Handbook of Multiple Sclerosis. London: Springer Healthcare; Handbook ISBN: Diagnostic guide ISBN:
9 Diagnosis Guidance for diagnostic investigation Making an accurate diagnosis, as early as possible, will allow for the timely use of disease-modifying therapy, while also removing uncertainty and allowing for informed career and family planning. However, with the push to make the diagnosis early, there is a possible increased risk of misdiagnosis. History When a diagnosis of MS is being considered, the patient history should focus on: - the range of neurologic symptoms; - the time course over which the neurologic symptoms developed/improved; - the effects of therapeutic interventions; and - manifestations that suggest the presence of other conditions/ms mimics. Physical examination Physical examination focuses on assessing the presence of neurologic manifestations to determine whether they indicate multifocal CNS involvement. Cerebrospinal fluid analysis Cerebrospinal fluid (CSF) examination is an important ancillary test for diagnosing MS that can provide additional support when clinical features and MRI are insufficient to make a definitive diagnosis. Typical CSF findings in MS Opening pressure Normal Glucose Normal Protein Normal in 2 out of 3 patients with MS, rarely >100 mg/dl Erythrocytes Leukocytes Microbiologic studies Cytology Intrathecal antibody production Measures of tissue injury Absent Absent in 2 out of 3 patients with MS, usually <50/mm 3, rarely >100 /mm 3 ; predominantly mononuclear cells Negative Negative Increased total immunoglobulin (Ig)G, increased IgG index and synthesis rate, (+) oligoclonal bands, or increased free kappa light chains Increased myelin basic protein
10 Diagnosis Magnetic resonance imaging MRI is utilized for the diagnosis of MS by demonstrating the presence of: - lesions typical of MS; - asymptomatic lesions indicating whether the criteria of anatomic dissemination and development of lesions over time are satisfied; and - lesions with imaging features atypical of MS (possible alternative diagnosis). In patients with known MS, MRI is also used to rule out development of a superimposed disease process. Revised consensus guidelines for MRI in MS have recently been published [13]. A B C D E F MRI lesions characteristic of MS. (A) Axial FLAIR image showing T2 lesions in periventricular white matter, centrum semiovale, subcortical white matter; (B) axial T1-weighted image showing rim and diffuse gadoliniumenhancing foci; (C) sagittal FLAIR image showing lesions in corpus callosum; (D) axial T2-weighted image showing right middle cerebellar peduncle lesion; (E) axial T2-weighted image showing a left midbrain peduncle lesion; (F) sagittal T2-weighted image of cervical spine showing multiple patchy lesions. Evoked potentials Evoked potentials are utilized to demonstrate subclinical involvement (slowed conduction) in CNS sensory pathways when the neurologic examination and MRI are insufficient to provide objective evidence of a multifocal disease process.
11 Diagnosis McDonald diagnostic criteria There is no pathognomonic clinical, laboratory, imaging finding, or combination of findings to diagnose MS and, ultimately, making a diagnosis involves weighing the evidence supporting MS against factors suggesting a different condition. Specifically, one assembles data by evaluating the following: - how the CNS is affected (ie, dissemination in space [DIS]); - the disease course (ie, dissemination in time [DIT]); - inflammatory features assessed by CSF or MRI examination; and - eliminating other likely causes. This diagnostic logic for MS is delineated in the currently used McDonald Criteria, a combination of clinical, imaging, and ancillary tests [14]. McDonald criteria for diagnosing MS Clinical presentation 2 relapses; objective clinical evidence of 2 lesions or objective clinical evidence of 1 lesion with reasonable historical evidence of a prior relapse 2 relapses; objective clinical evidence of 1 lesion 1 relapse; objective clinical evidence of 2 lesions 1 relapse; objective clinical evidence of 1 lesion (CIS) Insidious neurologic progression suggestive of MS Additional data needed for diagnosis None DIS, demonstrated by MRI or a further clinical relapse DIT, demonstrated by MRI or a further clinical relapse DIS, demonstrated by MRI or a second clinical relapse, and DIT, demonstrated by MRI or a second clinical relapse 1 year of disease progression plus two out of three of the following: evidence for DIS in the brain, demonstrated by MRI ( 1 T2 lesions) evidence for DIS in the spinal cord, demonstrated by MRI ( 2 T2 lesions) positive CSF DIS can be demonstrated by 1 T2 lesion in at least two out of four of the following areas : periventricular juxtacortical DIT can be demonstrated by a new T2 and/or Gd-enhancing lesion(s) on follow-up MRI, with reference to a baseline scan, irrespective of the timing of the baseline MRI; and simultaneous presence of asymptomatic Gd-enhancing and nonenhancing lesions at any time. Reproduced with permission from Polman et al [14] Wiley. infratentorial spinal cord
12 Diagnosis Differential diagnosis The potential differential diagnosis of MS is extensive [15] and it is useful to make a preliminary determination of which categories the patient belongs to before undertaking extensive testing: - clinical and imaging features classic for MS: cranial MRI and screening blood tests usually are sufficient; extensive testing is not needed; - initial episode typical of an MS relapse (CIS): commonly involves optic neuritis, a cerebral syndrome, brainstem syndrome, or patrial transvere myelitis; cranial MRI (plus spine MRI) and blood tests usually suffice (similar to classic MS); - MS plus additional superimposed condition: remain vigilant for the presence or development of an additional disease process in patients with known MS, as a superimposed disorder may explain/contribute to atypical manifestations; and - compatible with the diagnosis of MS but with atypical features ( red flags ): additional testing tailored to the clinical situation is necessary to confirm MS and eliminate other possibilities, such as an MS mimic. This includes the absence of expected features, especially in long-standing disease. Differential diagnosis of MS Monophasic CNS inflammatory demyelinating syndromes (ie, CIS): optic neuritis, cerebral, brainstem, partial transverse myelitis Fulminant idiopathic CNS inflammatory syndromes: acute disseminated encephalomyelitis, Devic s neuromyelitis optica, Marburg s disease, tumefactive MS, Baló s concentric sclerosis, Schilder disease Inflammatory/immune disorders: systemic lupus erythematosus, Sjögren s syndrome, Behçet s syndrome, Wegener s granulomatosis, polyarteritis nodosa, isolated CNS vasculitis, Susac s syndrome, Sneddon s syndrome, sarcoid, celiac disease, stiff-person syndrome, treatment with tumor necrosis factor blockers Infection: Lyme disease, syphilis, human immunodeficiency virus, human T cell lymphoma virus, progressive multifocal leukoencephalopathy, Whipple s disease, herpes viruses, mycoplasma, chlamydia Vascular: small vessel ischemia, migraine, emboli, antiphospholipid antibody syndrome, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, cavernous angioma of brainstem Genetic/degenerative: mitochondrial cytopathy, hereditary spastic paraplegia, hereditary cerebellar ataxias, presenilin-i disorders, leukodystrophies, adrenomyeloneuropathy, Fabry s disease, Alexander s disease, Niemann Pick disease, glutaryl-coenzyme A dehydrogenase deficiency, Pelizaeus Merzbacher disease, Krabbe s disease, olivopontocerebellar atrophy, motor neuron disease, hereditary episodic ataxias Metabolic: thyroid disease, vitamin B 12 deficiency, nitrous oxide intoxication, copper deficiency, porphyria Neoplastic: CNS lymphoma, intravascular lymphoma, metastasis, histiocytosis, paraneoplastic Spine: vascular malformations, tumor, degenerative spine disease
Clinical features. Chapter 2. Clinical manifestations. Course
Chapter 2 Clinical features Clinical manifestations The wide range of symptoms and signs of multiple sclerosis (MS) reflect multifocal lesions in the central nervous system (CNS), including in the afferent
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationThe Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
More informationMRI in Differential Diagnosis
MRI in Differential Diagnosis Jill Conway, MD, MA, MSCE Director, Carolinas MS Center Clerkship Director, UNCSOM-Charlotte Campus Charlotte, NC DISCLOSURES Speaking, consulting, and/or advisory boards
More informationAccuracy in Space and Time: Diagnosing Multiple Sclerosis. 2012 Genzyme Corporation, a Sanofi company.
Accuracy in Space and Time: Diagnosing Multiple Sclerosis 2012 Genzyme Corporation, a Sanofi company. Brought All rights to reserved. you by www.msatrium.com, MS.US.PO876.1012 your gateway to MS knowledge.
More informationMultiple Sclerosis: An imaging review and update on new treatments.
Multiple Sclerosis: An imaging review and update on new treatments. Dr Marcus Likeman Consultant Neuroradiologist North Bristol NHS Trust Bristol Royal Hospital for Children MRI appearances - White Matter
More informationMULTIPLE SCLEROSIS Update. Disclosures. Multiple Sclerosis. I do not have any disclosures. E. Torage Shivapour, M.D.
MULTIPLE SCLEROSIS Update E. Torage Shivapour, M.D. Clinical Professor Department of Neurology University of Iowa Hospitals & Clinics Disclosures I do not have any disclosures. Multiple Sclerosis Most
More informationMultiple Sclerosis. Matt Hulvey BL A - 615
Multiple Sclerosis Matt Hulvey BL A - 615 Multiple Sclerosis Multiple Sclerosis (MS) is an idiopathic inflammatory disease of the central nervous system (CNS) MS is characterized by demyelination (lesions)
More informationA Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
More information06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute
The Impact of Multiple Sclerosis in the Pacific Northwest James Bowen, MD Multiple Sclerosis Center Multiple Sclerosis Center Swedish Neuroscience Institute 1 2 Motor Symptoms of MS Weakness Spasticity
More informationAUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationMultiple Sclerosis (Dr. Merchut) 1. Pathophysiology
Multiple Sclerosis (Dr. Merchut) 1. Pathophysiology Multiple sclerosis (MS) is an acquired disorder with immune-mediated destruction of normal central nervous system (CNS) myelin with secondary loss of
More informationGuidance for evaluation of new neurological symptoms in patients receiving TYSABRI
Guidance for evaluation of new neurological symptoms in patients receiving TYSABRI Background information Progressive multifocal leukoencephalopathy (PML) PML is a demyelinating disease that attacks the
More information2.1 Who first described NMO?
History & Discovery 54 2 History & Discovery 2.1 Who first described NMO? 2.2 What is the difference between NMO and Multiple Sclerosis? 2.3 How common is NMO? 2.4 Who is affected by NMO? 2.1 Who first
More informationacquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare
Immunomodulatory Therapies in Pediatric MS Vuong Chinh Quyen Neurology Department Medscape Mar 8, 2013 Multiple Sclerosis in Children. Iran J Child Neurol. 2013 Spring Introduction acquired chronic immune-mediated
More informationClinically isolated syndrome (CIS)
Clinically isolated syndrome (CIS) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would
More informationMultiple Sclerosis Jeffrey M. Gelfand, MD
Multiple Sclerosis Jeffrey M. Gelfand, MD UCSF Multiple Sclerosis Center SFGH Neuroimmunology Clinic UCSF and SFGH Departments of Neurology Goals To review the fundamentals of neurological localization
More informationCNS DEMYLINATING DISORDERS
CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such
More informationLife with MS: Striving for Maximal Independence & Fulfillment
Life with MS: Striving for Maximal Independence & Fulfillment St. Louis, May 7, 2005 Florian P. Thomas, MA, MD, PhD MS Center, Department of Neurology Associate Professor, Saint Louis University Brain
More informationIII./5.3.: Multiple sclerosis. Epidemiology. Etiology. Pathology
III./5.3.: Multiple sclerosis Epidemiology Multiple sclerosis (MS) is the most common neuroimmunological disorder of the central nervous system. This chronic illness begins in early adulthood, mostly at
More informationTrauma Insurance Claims Seminar Invitation
Trauma Insurance Claims Seminar Invitation Introduction Since the development of Trauma Insurance in Australia in the 1980s, the product has evolved at a great pace. Some of the challenges faced by claims
More informationMULTIPLE SCLEROSIS 2015. Mercedes P Jacobson, MD, Department of Neurology Temple University School of Medicine
MULTIPLE SCLEROSIS 2015 Mercedes P Jacobson, MD, Department of Neurology Temple University School of Medicine Disclosure Research support, Sunovion and Marinus for epilepsy research Goals and Objectives
More informationOHTAC Recommendation
OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationWhat is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
More informationManaging the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner
Managing the Symptoms of Multiple Sclerosis Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner What is Multiple Sclerosis An autoimmune disease that affects the central nervous system (CNS) The immune
More informationHomework 5: Differential Diagnosis of Multiple Sclerosis
Homework 5: Differential Diagnosis of Multiple Sclerosis Due Wednesday, 3/3/99 1.0 Background Multiple Sclerosis affects approximately 350 K Americans and is the leading nontraumatic source of neurologic
More informationUsing the MS Clinical Course Descriptions in Clinical Practice
Using the MS Clinical Course Descriptions in Clinical Practice Mark J. Tullman, MD Director of Clinical Research The MS Center for Innovations in Care Missouri Baptist Medical Center Disclosures Consultant/speaking
More informationTransverse Myelitis ISBN 978-1-901893-57-1. A guide for patients and carers
Transverse Myelitis ISBN 978-1-901893-57-1 A guide for patients and carers The Brain and Spine Foundation provides support and information on all aspects of neurological conditions. Our publications are
More informationMultiple sclerosis (MS)
Multiple sclerosis (MS) Summary Multiple sclerosis (MS) is an incurable disease of the central nervous system that can affect the brain, spinal cord and optic nerves. The effects of MS are varied and unpredictable,
More informationCytokines pattern of Multiple Sclerosis patients treated with Apitherapy
Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Ahmad G. Hegazi, Khaled Al- Menabbawy, Eman H. Abd El- Rahman and Suzette I. Helal National Research Center, Dokki, Giza, Egypt
More informationß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate
ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents
More informationAUBMC Multiple Sclerosis Center
AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the
More informationSuspected cases of multiple sclerosis (MS) are usually young adults attending the neurology
J Neurol Neurosurg Psychiatry 2001;71(suppl II):ii3 ii8 MAKING THE DIAGNOSIS OF MULTIPLE SCLEROSIS J Palace *ii3 Suspected cases of multiple sclerosis (MS) are usually young adults attending the neurology
More informationMultifocal Motor Neuropathy. Jonathan Katz, MD Richard Lewis, MD
Multifocal Motor Neuropathy Jonathan Katz, MD Richard Lewis, MD What is Multifocal Motor Neuropathy? Multifocal Motor Neuropathy (MMN) is a rare condition in which multiple motor nerves are attacked by
More informationTHE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY
THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY John R. Rinker II, MD University of Alabama at Birmingham Birmingham VA Medical Center May 29, 2014 DISCLOSURES Salary/Research:
More informationParaneoplastic Antibodies in Clinical Practice. Mohammed El lahawi New Cross Hospital Wolverhampton
Paraneoplastic Antibodies in Clinical Practice Mohammed El lahawi New Cross Hospital Wolverhampton 1 Effects of Neoplasm Direct mass ( pressure ) effect Metastasis effect Remote effect 2 The Nervous System
More informationCAMBRIDGE UNIVERSITY CENTRE FOR BRAIN REPAIR A layman's account of our scientific objectives What is Brain Damage? Many forms of trauma and disease affect the nervous system to produce permanent neurological
More informationCBT IN THE CITY. adjusted to the news of being with MS? April 2013. Experts at your fingertips call now. Check out our new services in you local area
April 2013 Experts at your fingertips call now CBT IN THE CITY Check out our new services in you local area contents. A message from Susie, Information Multiple Sclerosis CBT can make a difference on the
More informationMultiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center
Multiple Sclerosis Update Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center None Disclosures First of All. Why is my talk in the Neurodegenerative hour? I respectfully object! Case
More information43. MULTIPLE SCLEROSIS
Guidelines to be followed by centres, services and units in order to be designated as Reference Centres, Services and Units of the National Health System, as agreed by the Interterritorial Board 43. MULTIPLE
More informationIF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)
IF YOU ARE RECEIVING (NATALIZUMAB) TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS Read the patient information leaflet that accompanies the medicine carefully. 1 This brochure is a supplement to the
More informationVoting for your top research questions Survey
MS Priority Setting Partnership Voting for your top research questions Survey Prioritising important research questions for multiple sclerosis a partnership between people affected by MS and healthcare
More informationPrimary progressive MS exposed. Alison Whittam
Primary progressive MS exposed Alison Whittam Primary progressive MS exposed Alison Whittam, Information Officer, MS Trust The MS Trust is a UK charity for people with MS, their family and friends. The
More informationUpdate: MRI in Multiple sclerosis
Nyt indenfor MS ved MR Update: MRI in Multiple sclerosis Hartwig Roman Siebner Danish Research Centre for Magnetic Resonance (DRCMR) Copenhagen University Hospital Hvidovre Dansk Radiologisk Selskabs 10.
More informationSupporting MS-Related Disability Claims to Private Insurers: The Physician s Role
Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role What Is This Guide? This guide was compiled by the National Multiple Sclerosis Society as an aid to health care professionals
More informationSummary chapter 2 chapter 2
Summary Multiple Sclerosis (MS) is a chronic disease of the brain and the spinal cord. The cause of MS is unknown. MS usually starts in young adulthood. In the course of the disease progression of neurological
More informationNEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso
NEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso Introduction Multiple sclerosis (MS), in its many and varied clinical forms,
More informationStuart B Black MD, FAAN Chief of Neurology Co-Medical Director: Neuroscience Center Baylor University Medical Center at Dallas
Billing and Coding in Neurology and Headache Stuart B Black MD, FAAN Chief of Neurology Co-Medical Director: Neuroscience Center Baylor University Medical Center at Dallas CPT Codes vs. ICD Codes Category
More informationChapter 10. Summary & Future perspectives
Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral
More informationThe Nature of MS. What We Know
The Nature of MS What We Know Multiple Sclerosis The most common chronic disease affecting the central nervous system (CNS) in young adults Clinically characterized by relapses and remissions of neurological
More informationUnderstanding. Multiple Sclerosis. Tim, diagnosed in 2004.
Understanding Multiple Sclerosis Tim, diagnosed in 2004. What Is Multiple Sclerosis? Multiple sclerosis (MS) is a neurologic disorder that affects the central nervous system (CNS). The CNS includes the
More informationWhat is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter
What is MS? 1 Neuron Damaged myelin due to inflammation MS is a chronic immunemediated disease that affects the central nervous system (CNS) Is a disease that affects both white and gray matter Interrupted
More informationSummary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary
Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease
More informationhttp://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387
http://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387! 388! http://my.fresnounified.org/personal/lygonza/gonzalez/neuron/neuron5synapse%20communication.png!! http://www.urbanchildinstitute.org/sites/all/files/databooks/2011/ch15fg25communication5between5neurons.jpg!!
More informationWelcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses. 26 April 2013
Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses 26 April 2013 1 Parkinson s Disease & Multiple Sclerosis Dr Nick Niven Jenkins 2 Movement Human
More informationMultiple Sclerosis: What You Need To Know. For Professionals
Multiple Sclerosis: What You Need To Know For Professionals What will I learn today? The Basics: What is MS? Living with MS: A Family Affair We Can Help: The National MS Society What MS Is: MS is thought
More informationThe Many Faces of MS
The Many Faces of MS Patricia A. Modica, OD, FAAO SUNY College of Optometry Kelly Malloy, OD, FAAO Pennsylvania College of Optometry at Salus University Multiple Sclerosis (MS) Most common acquired disease
More informationDevelopmental delay and Cerebral palsy. Present the differential diagnosis of developmental delay.
Developmental delay and Cerebral palsy objectives 1. developmental delay Define developmental delay Etiologies of developmental delay Present the differential diagnosis of developmental delay. 2. cerebral
More informationNEUROLOCALIZATION MADE EASY
NEUROLOCALIZATION MADE EASY Jared B. Galle, DVM, Diplomate ACVIM (Neurology) Dogwood Veterinary Referral Center 4920 Ann Arbor-Saline Road Ann Arbor, MI 48103 Localizing a neurologic problem to an anatomical
More informationMultiple Sclerosis (Diagnosis and Management of Current Therapies) Patient Safety William Sonnenberg, MD, Titusville
Multiple Sclerosis (Diagnosis and Management of Current Therapies) Patient Safety William Sonnenberg, MD, Titusville Disclosures: Speaker discloses that he is on the Speaker s Bureau for Forest Labs. The
More information09/05/2014. Painting pictures of the brain with numbers. Overview
Painting pictures of the brain with numbers Neurology for Insurers Dr Ian Cox & Adele Groyer (Gen Re) Overview Critical Illness Product Background Why should we be interested in neurology? Consult our
More informationAutoimmune Diseases More common than you think Randall Stevens, MD
Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system
More informationHow To Cover Occupational Therapy
Guidelines for Medical Necessity Determination for Occupational Therapy These Guidelines for Medical Necessity Determination (Guidelines) identify the clinical information MassHealth needs to determine
More informationClinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012. Reference : NHSCB/D4/c/1
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012 Reference : NHSCB/D4/c/1 NHS Commissioning Board Clinical Commissioning Policy: Disease
More informationDIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF MULTIPLE SCLEROSIS
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF MULTIPLE SCLEROSIS John R. Rinker, II, Anne H. Cross ABSTRACT Making the diagnosis of multiple sclerosis (MS) remains a challenging problem for clinicians. The foundation
More informationNew Treatment Options for MS Patients: Understanding risks versus benefits
New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS
More informationMultiple Sclerosis (MS)
Multiple Sclerosis (MS) Purpose/Goal: Care partners will have an understanding of Multiple Sclerosis and will demonstrate safety and promote independence while providing care to the client with MS. Introduction
More informationRELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010
RELAPSE MANAGEMENT Pauline Shaw MS Nurse Specialist 25 th June 2010 AIMS OF SESSION Relapsing/Remitting MS Definition of relapse/relapse rate Relapse Management NICE Guidelines Regional Clinical Guidelines
More informationMultiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate.
What is Multiple Sclerosis? Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate. A disease of the central nervous system
More informationSpinal Cord Diseases in Bernese Mountain Dogs
Spinal Cord Diseases in Bernese Mountain Dogs 0 A N O V E R V I E W F O R BERNER O W N E R S O R G A N I Z E D B Y N A N C Y M E L O N E, P H. D. Based on materials obtained from the Berner Garde Foundation
More informationMellen Center Approaches: Pain in Multiple Sclerosis
Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research 216.444.8600 Mellen Center Approaches: Pain in Multiple Sclerosis How often do MS patients have pain? The point prevalence of
More informationNew perception of disability including cognition, fatigue, pain and other impairments related to MS
New perception of disability including cognition, fatigue, pain and other impairments related to MS Diego Cadavid, MD Director, MS Clinical Development Biogen Idec 1 Need for clarity on terminology for
More informationHow To Use A Drug In Multiple Sclerosis
Revised (2009) guidelines for prescribing in multiple sclerosis INTRODUCTION In January 2001, the (ABN) first published guidelines for the use of licensed disease modifying treatments (ß-interferon and
More informationReversibility of Acute Demyelinating Lesions in relapsingremitting
Reversibility of Acute Demyelinating Lesions in relapsingremitting Multiple Sclerosis Omar A. Khan ( Division of Neuroimmunology, Department of Neurology, Neurology and Research Services. Veterans Affairs
More informationSpine University s Guide to Cauda Equina Syndrome
Spine University s Guide to Cauda Equina Syndrome 2 Introduction Your spine is a very complicated part of your body. It s made up of the bones (vertebrae) that keep it aligned, nerves that channel down
More informationCoping with Symptoms of Multiple Sclerosis
Coping with Symptoms of Multiple Sclerosis Josée Poirier B. Sc. Nursing, MSCN Outline What Is a Pseudo exacerbation? Awareness Advancement of Treatments Treatment of Symptoms Uhthoff s Phenomenon What
More informationMariusz Stasiołek Neurology Department Polish Mother s Memorial Hospital Research Institute, Lodz
Therapeutic Plasma Exchange in Multiple Sclerosis Relapses Mariusz Stasiołek Neurology Department Polish Mother s Memorial Hospital Research Institute, Lodz MS heterogeneity Multiple Sclerosis differences
More informationMultiple sclerosis. Great Ormond Street Hospital for Children NHS Foundation Trust: Information for young people. What is Multiple Sclerosis?
Great Ormond Street Hospital for Children NHS Foundation Trust: Information for young people Multiple sclerosis When young people are told that they have a diagnosis of Multiple Sclerosis (MS) they usually
More informationTaylor Slotte Pathology Disease Report Spring 2014 Multiple Sclerosis
Taylor Slotte Pathology Disease Report Spring 2014 Multiple Sclerosis Abstract Multiple sclerosis (MS) is a chronic autoimmune disorder that attacks the body s central nervous system. It affects the brain,
More informationOptic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.
Optic Neuritis Your doctor thinks that you have had an episode of optic neuritis. This is the most common cause of sudden visual loss in a young patient. It is often associated with discomfort in or around
More informationCanadian Multiple Sclerosis Monitoring System: Environmental and Technical Scan
pic pic pic Canadian Multiple Sclerosis Monitoring System: Environmental and Technical Scan Standards and Data Submission Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead
More informationAbout MS. An introduction to. An introduction to multiple sclerosis for people who have recently been diagnosed. What is MS? Is it common?
An introduction to multiple sclerosis for people who have recently been diagnosed When you have just been diagnosed with multiple sclerosis, you will probably have many questions about the condition and
More informationNeurosarcoidosis. Jeffrey M. Gelfand, MD
Neurosarcoidosis WASOG Meeting Cleveland October 2012 Patient Education Session Relevant Financial Disclosures: None Jeffrey M. Gelfand, MD Assistant Professor of Clinical Neurology UCSF MS Center, Dept
More informationNatalizumab (Tysabri) and PMLthe current figures. Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY
Natalizumab (Tysabri) and PMLthe current figures Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY Humanised MAB Natalizumab Specific binding to a4-integrin
More informationVictorian Nurse Practitioner Project Phase 4, Round 4.11 - Chronic Disease Management
Victorian Nurse Practitioner Project Phase 4, Round 4.11 - Chronic Disease Management Eastern Health Multiple Sclerosis Nurse Practitioner Service Model April 2014 Prepared by Jodi Haartsen and Deanna
More informationClinical Trials of Disease Modifying Treatments
MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To
More informationFUNCTIONAL EEG ANALYZE IN AUTISM. Dr. Plamen Dimitrov
FUNCTIONAL EEG ANALYZE IN AUTISM Dr. Plamen Dimitrov Preamble Autism or Autistic Spectrum Disorders (ASD) is a mental developmental disorder, manifested in the early childhood and is characterized by qualitative
More informationChapter 43: The Immune System
Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2
More informationNEUROIMAGING in Parkinsonian Syndromes
NEUROIMAGING in Parkinsonian Syndromes (Focus on Structural Techniques: CT and MRI) Dr. Roberto Cilia Parkinson Institute, ICP, Milan, Italy OUTLINE Primary Parkinsonism Idiopathic Parkinson s Disease
More informationDisclosure Statement. Multiple Sclerosis: Current Trends in Treatment. Epidemiology of MS. Multiple Sclerosis. Viral Link to MS.
Disclosure Statement Multiple Sclerosis: Current Trends in Treatment Member of Speaker s Bureau Biogen Idec Will discuss non FDA approved therapies Christine St Laurent MSN, RN, MSCN 19 th Annual Mud Season
More informationALS and Lyme Disease Questions from Patient and Families Responses from Medical Experts
ALS and Lyme Disease Questions from Patient and Families Responses from Medical Experts Introduction: When anyone receives a diagnosis of ALS, it is normal and understandable to ask why you ve developed
More informationQ A. The Evolving Management of MS. Multiple sclerosis (MS) is one of the most. What GPs Need to Know. What is the clinical course of MS?
& s The Evolving Management of MS What GPs Need to Know Khalid Hassan, LRCP&SI, MB, BCh, BO; and Liesly Lee, MSc, MD, FRCP(C) s presented at a University of Toronto CME Conference (November 2003) Multiple
More informationSECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage
SECTION 2 Multiple Sclerosis (MS) Drug Coverage Section 2 Multiple Sclerosis (MS) Drug Coverage ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Selected Drug Products used in the treatment of patients with
More informationWhat is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician
What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician Overview of presentation Case history Video example pre and post treatment Historical review PD in the UK Epidemiology and aetiology Making
More informationAutoimmunity. Autoimmunity. Genetic Contributions to Autoimmunity. Targets of Autoimmunity
Autoimmunity Factors predisposing an individual to autoimmune disease Mechanisms of initiation of autoimmunity Pathogenesis of particular autoimmune disease Animal models of autoimmune disease Treatment
More informationMULTIPLE SCLEROSIS. Mary Beth Rensberger, RN, BSN, MPH Author
MULTIPLE SCLEROSIS Mary Beth Rensberger, RN, BSN, MPH Author All rights reserved. Purchasers of this module are permitted to reproduce the forms contained herein for their individual internal use only.
More informationThere's no cure for multiple sclerosis. However treatments can help treat attacks, modify the course of the disease and treat symptoms.
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationBrain Spots on Imaging Tests
Brain Spots on Imaging Tests To Be or Not to Be Concerned Metropolitan Underwriting Discussion Group 1/29/13 Charles Levy, MD Aviva USA CT and MRI 2 most common forms of brain imaging today As with any
More information